Alpha DNA Investment Management’s AdvisorShares Alpha DNA Equity Sentiment ETF SENT Stock Holding History

Alpha DNA Investment Management’s Portfolio SENT Stock Details SENT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-27,323	Closed	-$608K	–	248
2023 Q3	$608K	Buy	27,323 +9,213	+51%	+$217K	0.25%	84
2023 Q2	$437K	Sell	18,110 -49,622	-73%	-$1.13M	0.15%	138
2023 Q1	$1.57M	Buy	67,732 +23,925	+55%	+$556K	0.46%	30
2022 Q4	$989K	Sell	43,807 -1,276	-3%	-$29.3K	0.35%	131
2022 Q3	$975K	Sell	45,083 -33,982	-43%	-$747K	0.81%	36
2022 Q2	$1.64M	Buy	79,065 +23,557	+42%	+$526K	1.4%	2
2022 Q1	$1.33M	Buy	55,508 +11,800	+27%	+$291K	0.93%	33
2021 Q4	$1.21M	Sell	43,708 -24,725	-36%	-$682K	0.76%	95
2021 Q3	$1.83M	Buy	68,433 +7,267	+12%	+$199K	1.25%	3
2021 Q2	$1.69M	Buy	61,166 +6,562	+12%	+$176K	1.15%	20
2021 Q1	$1.41M	Buy	+54,604	New	+$1.42M	1.62%	4

Alpha DNA Investment Management's SENT Position: Q4 2023 in Review

Alpha DNA Investment Management sold out of AdvisorShares Alpha DNA Equity Sentiment ETF (SENT) in Q4 2023, closing a stake of 27,323 shares — an estimated $608K sold.

Alpha DNA Investment Management first reported a position in SENT in Q1 2021 and held it in 11 quarters. The position peaked at $1.83M in Q3 2021. 0 funds tracked by Wall St. Rank hold SENT as of Q4 2023.

Alpha DNA Investment Management reported no remaining AdvisorShares Alpha DNA Equity Sentiment ETF position as of Q4 2023 after selling out during the quarter.
Alpha DNA Investment Management sold 27,323 AdvisorShares Alpha DNA Equity Sentiment ETF shares in Q4 2023, an estimated $608K.
Alpha DNA Investment Management first reported a position in AdvisorShares Alpha DNA Equity Sentiment ETF in Q1 2021 and held it in 11 quarters.
Alpha DNA Investment Management's AdvisorShares Alpha DNA Equity Sentiment ETF position peaked at $1.83M in Q3 2021.
0 funds tracked by Wall St. Rank held AdvisorShares Alpha DNA Equity Sentiment ETF as of Q4 2023.

Based on Alpha DNA Investment Management's 13F filing for Q4 2023, filed 12 Feb 2024.